Skip to main content

Drug Interactions between Ibsrela and Ocular Vitamins with Lutein

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between Ibsrela and Ocular Vitamins with Lutein. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Ibsrela

A total of 0 drugs are known to interact with Ibsrela.

Ocular Vitamins with Lutein

A total of 103 drugs are known to interact with Ocular Vitamins with Lutein.

Drug and food interactions

Moderate

tenapanor food

Applies to: Ibsrela (tenapanor)

ADJUST DOSING INTERVAL: Administration of tenapanor immediately before a meal may enhance its effectiveness. In clinical trials, administration of tenapanor 5 to 10 minutes before a meal increased the 24-hour stool sodium excretion compared to taking tenapanor in the fed or fasting state. The resulting higher levels of sodium in the intestine and colon cause an increase in water secretion into the intestinal lumen, which accelerates intestinal transit time and results in a softer stool consistency.

MANAGEMENT: The manufacturer recommends administering tenapanor immediately prior to breakfast or the first meal of the day and immediately prior to dinner.

References (1)
  1. (2019) "Product Information. Ibsrela (tenapanor)." Ardelyx, Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer